Showing results (1731-1740 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|June 28, 2018
Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reactionKei Kunimasa, Taiki Isei, Harumi Nakamura, et al.
Investigational New Drugs|January 1, 1986
The effects of bisantrene on human plateletsM E Rybak, B Badstubner, T Griffin
Investigational New Drugs|January 1, 1986
Phase II trial of nimustine (ACNU; 3-[4-amino-2-methyl-5-pyrimidinyl) methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride) in patients with small cell carcinoma of the lung after failure on combination chemotherapyR A Joss, P Siegenthaler, C Ludwig, et al.
Investigational New Drugs|August 8, 2018
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancerNavid Sobhani, Daniele Generali, Alberto D'Angelo, et al.
Investigational New Drugs|August 8, 2018
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)Paul Monk, Glenn Liu, Walter M Stadler, et al.
Investigational New Drugs|July 13, 2018
Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trialChristian Dittrich, Robert Königsberg, Martina Mittlböck, et al.
Investigational New Drugs|February 12, 2010
The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in ratsMeihong Deng, Hai Huang, Hao Jin, et al.
Investigational New Drugs|September 22, 2016
A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumorsAlex A Adjei, Patricia LoRusso, Antoni Ribas, et al.
Investigational New Drugs|September 8, 2016
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibodyNobuaki Mamesaya, Hirotsugu Kenmotsu, Mineo Katsumata, et al.
Investigational New Drugs|September 9, 2016
A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinibTing Li, Lei Wang, Huijie Wang, et al.
Pageof 372